Related Experiment Videos
Treatment of ischemic heart disease in the 1990s: key issues for the physician
1Department of Medical Cardiology, University of Leeds, England.
Insights
Physicians can now manage ischemic heart disease symptoms with drugs like nicorandil. True progress requires addressing risk factors to slow or reverse the condition, bridging the knowledge-practice gap.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Understanding of ischemic heart disease (IHD) pathology and risk has grown significantly.
- A gap persists between IHD knowledge and clinical application.
- Pharmacotherapy for IHD presents ongoing challenges.
Purpose of the Study:
- To highlight the current therapeutic dilemmas in managing IHD.
- To emphasize the need for a comprehensive approach combining treatment and prevention.
- To discuss the role of modern anti-ischemic drugs in IHD management.
Main Methods:
- Review of current understanding of IHD pathology and pathophysiology.
- Discussion of pharmacotherapeutic strategies for symptom alleviation.
- Emphasis on risk factor correction for disease retardation.
Main Results:
- Modern anti-ischemic drugs, such as nicorandil, can effectively manage IHD symptoms and hemodynamic derangements.
- Correction of secondary risk factors is crucial for retarding or reversing IHD progression.
- A comprehensive approach integrating treatment and prevention is essential.
Conclusions:
- While symptoms of IHD are manageable, long-term goals require addressing underlying risk factors.
- Bridging the gap between IHD knowledge and practice necessitates a dual focus on treatment and prevention.
- Future strategies must aim for disease retardation and regression through risk factor modification.
Abstract:
During recent years, understanding of the basic pathology, pathophysiology, and morbid risk of ischemic heart disease has increased immensely, but a wide gulf still exists between such knowledge and its practical application to the individual patient. Although the treatment of ischemic heart disease continues to pose many dilemmas for the physician in the 1990s, the key issues are easy to define, particularly with regard to pharmacotherapy. The basic pathologic processes and their rate of development and progression, their pathophysiologic consequences, and their morbidity and mortality risks are becoming increasingly clear. Until methods are developed to reconstitute the obstructed coronary arteries, clinical attention must be directed primarily to alleviating symptoms and ECG signs of myocardial ischemia and improving the deranged hemodynamic disorder. These primary objectives are now achievable with modern anti-ischemic drugs such as nicorandil. With the availability of efficacious drugs against clinical symptoms, ECG signs, and hemodynamic associates of ischemic heart disease, clinical attention must be redirected to retardation or even regression of the primary myocardial ischemic syndrome. This therapeutic goal can be achieved only by correction of the secondary risk factors that are present in many patients with ischemic heart disease. Only by such a comprehensive approach, namely, that of treatment allied to prevention, can the gap between knowledge and its practical application to the individual patient be narrowed.(ABSTRACT TRUNCATED AT 250 WORDS)